Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05551598 (ClinicalTrials.gov)	November 15, 2022	20/9/2022	Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)	A Randomized, Double-blind, Placebo-controlled Phase ? Clinical Study to Evaluate the Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)	Neuromyelitis Optica Spectrum Disorder	Drug: Mitoxantrone Hydrochloride Liposome Injection	CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.	NULL	Not yet recruiting	18 Years	60 Years	All	45	Phase 2	NULL
2	NCT05496894 (ClinicalTrials.gov)	August 2022	28/7/2022	A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis	A Phase ? Study to Evaluate the Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis	Relapsing Multiple Sclerosis	Drug: Mitoxantrone Hydrochloride Liposome Injection	CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.	NULL	Withdrawn	18 Years	55 Years	All	0	Phase 2	China